Tiens Biotech Group Usa Inc - Statement of Changes in Beneficial Ownership (4)
24 Septembre 2008 - 3:33AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Expires:
February 28, 2011
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
LI JINYUAN
|
2. Issuer Name
and
Ticker or Trading Symbol
TIENS BIOTECH GROUP USA INC
[
TBV
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
__
X
__ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
CFO and President
|
(Last)
(First)
(Middle)
NO. 6 YUANQUAN ROAD, WUQING NEW-TECH INDUSTRIAL PARK
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
9/19/2008
|
(Street)
TIANJIN, F4 301700
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock, par value $0.001 per share
|
9/19/2008
|
|
P
|
|
1995000
|
A
|
(1)
|
67830000
|
I
|
See Footnote
(2)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Explanation of Responses:
|
(
1)
|
TIENS (USA) Investment Holdings Group Overseas Limited, a British Virgin Islands Company, purchased 1,995,000 shares of
common stock, par value $0.001 per share, of Tiens Biotech Group (USA), Inc. from Jiao Wen Jun, Yan Yu Peng and Bai Ping for
a total consideration of $3 pursuant to three separate Share Transfer Agreements dated September 19, 2008
|
(
2)
|
The shares are owned by TIENS (USA) Investment Holding Group Overseas Limited ("TIENS USA"). As sole director of TIENS USA,
Mr. Li has voting and dispositive power over the shares. Mr. Li disclaims beneficial ownership of the shares owned by TIENS
USA, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities
for purposes of Section 16 or for any other purpose.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
LI JINYUAN
NO. 6 YUANQUAN ROAD
WUQING NEW-TECH INDUSTRIAL PARK
TIANJIN, F4 301700
|
X
|
X
|
CFO and President
|
|
Signatures
|
/s/ Jinyuan Li
|
|
9/23/2008
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Tiens Biotech GR Usa (AMEX:TBV)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Tiens Biotech GR Usa (AMEX:TBV)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024
Real-Time news about Tiens Biotech Grp. (Usa) Common Stock (American Stock Exchange): 0 recent articles
Plus d'articles sur Tiens Biotech Group Usa Inc